BLOOD RESEARCH Volume 49ㆍNumber 1ㆍMarch 2014

First Page		Document Content
Nucleosides Triazines Acute leukemia Acute myeloid leukemia Myelodysplastic syndrome Chronic myelomonocytic leukemia Azacitidine Myeloid sarcoma Decitabine Oncology Medicine Myeloid leukemia		BLOOD RESEARCH Volume 49ㆍNumber 1ㆍMarch 2014 Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 581,75 KB Share Document on Facebook

	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma DocID: 15uOM - View Document
	Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc DocID: 11pE5 - View Document
	Astex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AML DUBLIN, Calif.--(BUSINESS WIRE)-- Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the DocID: 11oeo - View Document
	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As DocID: 11odm - View Document
	Eisai and Janssen Announce the Presentation of DACOGEN® (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia Data from DACO-016 study at 2011 American Society of Clinical Oncology Ann DocID: 11o2S - View Document